Back to Newsroom

International Stem Cell Corporation Develops Technology to Replace Cartilage for the Treatment of Osteoarthritis

CARLSBAD, CA–(Marketwired – September 30, 2015) – International Stem Cell Corporation (OTCQB: ISCO)(, ISCO or the Company), a California-based biotechnology company developing novel stem cell-based therapies, today announced that the Company’s scientific team has developed a robust innovative technology to generate functional articular cartilage from the patient’s own skin or adipose tissue to treat osteoarthritis. This breakthrough technology may allow ISCO to not only address the therapeutic needs of patients suffering from osteoarthritic knee joints, but to also treat those with shoulder joints and intervertebral spinal disk osteoarthritis.

Click here to read the full release